恩替卡韦联合鳖甲软肝片降低中国慢性乙型肝炎患者肝细胞癌风险
本研究基于双盲随机安慰剂对照试验的延伸开放标签阶段,评估恩替卡韦联合鳖甲软肝片能否进一步降低Ishak纤维化评分≥3分的初治中国慢性乙型肝炎患者的肝细胞癌风险。共纳入1000例患者,改良意向治疗人群中联合治疗组7年肝细胞癌累积发生率为4.7%,显著低于恩替卡韦单药组的9.3%(p=0.008)。结论认为联合治疗可进一步降低肝细胞癌和肝病相关死亡风险。
要点
- 恩替卡韦联合鳖甲软肝片组7年肝细胞癌累积发生率为4.7%,低于单药组的9.3%(p=0.008)。
- 联合治疗组7年肝病相关死亡累积发生率为0.2%,低于单药组的2.2%(p=0.030)。
- 第72周未实现纤维化逆转者中,联合治疗组肝细胞癌发生率仍低于单药组(p=0.018)。
核心结论
- 恩替卡韦联合鳖甲软肝片可进一步降低慢性乙型肝炎合并晚期纤维化或肝硬化患者的肝细胞癌风险和肝病相关死亡风险,可能对肝细胞癌预防具有重要临床意义。
研究设计与样本
- 研究为父级双盲随机安慰剂对照试验的延伸开放标签治疗阶段,研究对象为初治中国慢性乙型肝炎且Ishak纤维化评分≥3分的患者。
- 经过72周恩替卡韦联合鳖甲软肝片与恩替卡韦联合安慰剂的比较后,参与者进入开放标签治疗阶段,每6个月随访一次。
- 共招募1000例患者,中位年龄42.0岁,男性占69.9%,HBeAg阳性占58.3%。
- 主要终点为肝细胞癌发生率,次要终点为肝病相关死亡、非肝细胞癌事件和非肝病相关死亡。
- 采用改良意向治疗、意向治疗和符合方案人群进行时间至事件分析。
主要发现
- 改良意向治疗人群中,恩替卡韦联合鳖甲软肝片组7年肝细胞癌累积发生率为4.7%,恩替卡韦单药组为9.3%(p=0.008)。
- 改良意向治疗人群中,恩替卡韦联合鳖甲软肝片组7年肝病相关死亡累积发生率为0.2%,恩替卡韦单药组为2.2%(p=0.030)。
- 第72周未实现纤维化逆转的患者中,恩替卡韦联合鳖甲软肝片组肝细胞癌发生率低于恩替卡韦单药组(p=0.018)。
- 两组在其他2个次要终点或安全性特征方面无差异。
- 包含治疗分配参数的多变量Cox比例回归分析显示,恩替卡韦联合鳖甲软肝片治疗与肝细胞癌发生率降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. METHODS: After a 72-week comparison between ETV+BRC and ETV+placebo treatment, participants were eligible to enter an open-label treatment phase and were followed up every 6 months. The primary [secondary] endpoints were the incidence of HCC [liver-related deaths, non-HCC events, and non-liver-related deaths]. Modified intention-to-treat (mITT), intention-to-treat (ITT), and per-protocol (PP) populations were defined for the time-to-event analysis. RESULTS: A total of 1,000 patients were recruited; the median age was 42.0 years; 69.9% were male and 58.3% were HBeAg positive. In the mITT population, the 7-year cumulative incidence of HCC [liver-related deaths] was 4.7% [0.2%] for ETV+BRC, which was significantly lower than 9.3% [2.2%] for ETV monotherapy (p = 0.008 [p = 0.030]). Notably, ETV+BRC treatment yielded a lower incidence of HCC in those who did not achieve regression of fibrosis at week 72 than ETV monotherapy (p = 0.018). There were no differences in the other 2 secondary endpoints or safety profiles between the groups. Multivariable Cox proportional regression analysis, including the treatment allocation as a parameter, also demonstrated that ETV+BRC treatment was associated with a reduced incidence of HCC. The ITT and PP analyses showed consistent results. CONCLUSIONS: ETV plus BRC combination treatment could further reduce the risk of HCC and liver-related deaths in patients with CHB and advanced fibrosis or cirrhosis, which may have important clinical implications for HCC prevention. LAY SUMMARY: Patients with chronic hepatitis B virus infection are at an increased risk of developing liver cancer (specifically hepatocellular carcinoma [HCC]). While there are effective antiviral treatments that can suppress the virus in chronically infected patients, the risk of HCC remains. Herein, we show that adding a traditional Chinese medicine called Biejia-Ruangan compound to an antiviral reduced the risk of HCC in patients with chronic hepatitis B.
引用
- Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022. PMID: 35985545. doi:10.1016/j.jhep.2022.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。